sexta-feira, 2 de outubro de 2026
PesquisarExplore
pt.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· February 9, 2026

WISeKey’s WISe.Art and GMA Once Again Revolutionize the Future of Art and Technology in an Extraordinary Event in Venice

View original at globenewswire.com
WISeKey’s WISe.Art and GMA Once Again Revolutionize the Future of Art and Technology in an Extraordinary Event in Venice WISeKey’s WISe.Art and GMA Once Again Revolutionize the Future of Art and Technology in an Extraordinary Event in Venice Geneva, Switzerland, February 9, 2026 – WISeKey International Holding Ltd (“WI…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The technologies do not replace the artist, but rather amplify creative capacity, protect artworks, and enable global dissemination

    80% confidence

  • Post-quantum cryptography leveraging SEALSQ's quantum-resistant technologies future-proofs artworks against the next generation of cyber threats and quantum computing attacks

    80% confidence

  • WISe.ART is built on WISeKey's deep expertise in cybersecurity, digital identity, and blockchain technologies offering a secure and sovereign NFT ecosystem

    80% confidence

  • Venice will become the global laboratory of a new creative era, where technological innovation is placed at the service of artistic expression and human values

    80% confidence

  • The future of art passes through technology, but remains profoundly human

    80% confidence

  • WISeSat constellation enables art projects that are globally accessible, resilient, and independent of traditional terrestrial networks

    80% confidence

Citado nestas reportagens da Via News

O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
AI-Driven Drug Development Meets Biotech Deal-Making and Regulatory Catalysts
AI-designed therapeutics (Insilico's rentosertib showing biological-age reductions) are moving into the clinical mainstream. Large-cap biotech is simultaneously reallocating capital through M&A (Lilly–Merida, $2.9B) and government funding (BARDA–Basilea), while trial failures (ziltivekimab, a 9.4% Novo Nordisk share drop) and upcoming FDA catalysts (the ivonescimab PDUFA on 2026-11-14) drive volatility. The wider AI regulatory and legal climate (Tesla Cybercab probe, xAI's Minnesota loss, OpenAI suits) is tightening, though QAIAx's micro-cap trial claims are speculative and weakly connected.
A nossa leitura dos dados ›
Sinais que acompanhamos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,985
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,985 factos verificados com a fonte5,327 documentos-fonte arquivados
Consulte estes dados → isubstrate.com